Adverse Events with Sustained-Release Donepezil in Alzheimer Disease

Chunsoo Lee; Kyungsang Lee; Hyewon Yu; Seung Ho Ryu; Seok Woo Moon; Changsu Han; Jun Young Lee; Young Min Lee; Shin Gyeom Kim; Ki Woong Kim; Dong Woo Lee; Seong Yoon Kim; Sang Yeol Lee; Jae Nam Bae; Young Eun Jung; Jeong Lan Kim; Byung Soo Kim; Il Seon Shin; Young Hoon Kim; Bong Jo Kim; Hyo Shin; Woojae Myung; Bernard J. Carroll; Doh Kwan Kim

doi:10.1097/JCP.0000000000000726

Adverse Events with Sustained-Release Donepezil in Alzheimer Disease

Chunsoo Lee
, Kyungsang Lee
, Hyewon Yu
, Seung Ho Ryu
, Seok Woo Moon
, Changsu Han
, Jun Young Lee
, Young Min Lee
, Shin Gyeom Kim
, Ki Woong Kim
, Dong Woo Lee
, Seong Yoon Kim
, Sang Yeol Lee
, Jae Nam Bae
, Young Eun Jung
, Jeong Lan Kim
, Byung Soo Kim
, Il Seon Shin
, Young Hoon Kim
, Bong Jo Kim

Hyo Shin, Woojae Myung, Bernard J. Carroll, Doh Kwan Kim^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Purpose/Background: Sustained-releasehigh-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trialbody weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures: To clarify whether this finding is consistent across ethnic groups that vary in absolute body masswe recruited Korean patients aged 45 to 90 years with moderate to severe AD who had been receiving standard donepezil immediate release 10mg/d for at least 3months.

Original language	English
Pages (from-to)	401-404
Number of pages	4
Journal	Journal of Clinical Psychopharmacology
Volume	37
Issue number	4
DOIs	https://doi.org/10.1097/JCP.0000000000000726
Publication status	Published - 2017 Aug 1
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2017 Wolters Kluwer HealthInc. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alzheimer disease
adverse effects
body mass index
clinical trial
donepezil

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1097/JCP.0000000000000726

Cite this

Lee, C., Lee, K., Yu, H., Ryu, S. H., Moon, S. W., Han, C., Lee, J. Y., Lee, Y. M., Kim, S. G., Kim, K. W., Lee, D. W., Kim, S. Y., Lee, S. Y., Bae, J. N., Jung, Y. E., Kim, J. L., Kim, B. S., Shin, I. S., Kim, Y. H., ... Kim, D. K. (2017). Adverse Events with Sustained-Release Donepezil in Alzheimer Disease. Journal of Clinical Psychopharmacology, 37(4), 401-404. https://doi.org/10.1097/JCP.0000000000000726

Lee, C, Lee, K, Yu, H, Ryu, SH, Moon, SW, Han, C, Lee, JY, Lee, YM, Kim, SG, Kim, KW, Lee, DW, Kim, SY, Lee, SY, Bae, JN, Jung, YE, Kim, JL, Kim, BS, Shin, IS, Kim, YH, Kim, BJ, Shin, H, Myung, W, Carroll, BJ & Kim, DK 2017, 'Adverse Events with Sustained-Release Donepezil in Alzheimer Disease', Journal of Clinical Psychopharmacology, vol. 37, no. 4, pp. 401-404. https://doi.org/10.1097/JCP.0000000000000726

@article{d8b87c46e3834ca58b3be11dea3d7dd0,

title = "Adverse Events with Sustained-Release Donepezil in Alzheimer Disease",

abstract = "Purpose/Background: Sustained-releasehigh-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trialbody weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures: To clarify whether this finding is consistent across ethnic groups that vary in absolute body masswe recruited Korean patients aged 45 to 90 years with moderate to severe AD who had been receiving standard donepezil immediate release 10mg/d for at least 3months.",

keywords = "Alzheimer disease, adverse effects, body mass index, clinical trial, donepezil",

author = "Chunsoo Lee and Kyungsang Lee and Hyewon Yu and Ryu, \{Seung Ho\} and Moon, \{Seok Woo\} and Changsu Han and Lee, \{Jun Young\} and Lee, \{Young Min\} and Kim, \{Shin Gyeom\} and Kim, \{Ki Woong\} and Lee, \{Dong Woo\} and Kim, \{Seong Yoon\} and Lee, \{Sang Yeol\} and Bae, \{Jae Nam\} and Jung, \{Young Eun\} and Kim, \{Jeong Lan\} and Kim, \{Byung Soo\} and Shin, \{Il Seon\} and Kim, \{Young Hoon\} and Kim, \{Bong Jo\} and Hyo Shin and Woojae Myung and Carroll, \{Bernard J.\} and Kim, \{Doh Kwan\}",

year = "2017",

month = aug,

day = "1",

doi = "10.1097/JCP.0000000000000726",

language = "English",

volume = "37",

pages = "401--404",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Adverse Events with Sustained-Release Donepezil in Alzheimer Disease

AU - Lee, Chunsoo

AU - Lee, Kyungsang

AU - Yu, Hyewon

AU - Ryu, Seung Ho

AU - Moon, Seok Woo

AU - Han, Changsu

AU - Lee, Jun Young

AU - Lee, Young Min

AU - Kim, Shin Gyeom

AU - Kim, Ki Woong

AU - Lee, Dong Woo

AU - Kim, Seong Yoon

AU - Lee, Sang Yeol

AU - Bae, Jae Nam

AU - Jung, Young Eun

AU - Kim, Jeong Lan

AU - Kim, Byung Soo

AU - Shin, Il Seon

AU - Kim, Young Hoon

AU - Kim, Bong Jo

AU - Shin, Hyo

AU - Myung, Woojae

AU - Carroll, Bernard J.

AU - Kim, Doh Kwan

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose/Background: Sustained-releasehigh-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trialbody weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures: To clarify whether this finding is consistent across ethnic groups that vary in absolute body masswe recruited Korean patients aged 45 to 90 years with moderate to severe AD who had been receiving standard donepezil immediate release 10mg/d for at least 3months.

AB - Purpose/Background: Sustained-releasehigh-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trialbody weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures: To clarify whether this finding is consistent across ethnic groups that vary in absolute body masswe recruited Korean patients aged 45 to 90 years with moderate to severe AD who had been receiving standard donepezil immediate release 10mg/d for at least 3months.

KW - Alzheimer disease

KW - adverse effects

KW - body mass index

KW - clinical trial

KW - donepezil

UR - https://www.scopus.com/pages/publications/85020255822

U2 - 10.1097/JCP.0000000000000726

DO - 10.1097/JCP.0000000000000726

M3 - Article

C2 - 28590369

AN - SCOPUS:85020255822

SN - 0271-0749

VL - 37

SP - 401

EP - 404

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

IS - 4

ER -

Adverse Events with Sustained-Release Donepezil in Alzheimer Disease

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this